@oristarA,
oristarA wrote:
The "the subset of HIV isolates " is confusing.
Who would like to explain it in a bit more detail?
Context:
While the scientists were unsuccessful so far in crystallizing PG16's sister molecule PG9, they were able to glean insight into its action from biochemical studies using both molecules. By switching a small (seven-amino acid) segment of the CDR3 subdomain of PG9 for a similar segment from PG16, the team changed the subset of HIV isolates neutralized by the antibody. This confirmed the loop in question was the "business end" of the antibody and suggested that it might be possible to create other interesting variants of the antibody by manipulating this region.
This is my best guess.
HIV is constantly mutating, so there are multiple HIV strains.
PG9 kills some strains (a subset of HIV viruses) PG16 kills some other strains ( a different subset of HIV viruses).
By switching a small segment of PG9 for a similar segment from PG16, the strain(s) of HIV nutralised were different.